Board of Directors

Jonathan Behr, PhD

Dementia Discovery Fund

Jonathan Behr, PhD, is a partner at the Dementia Discovery Fund (DDF) and also serves on the boards of directors of Nitrome Biosciences and Tiaki Therapeutics. Prior to joining the DDF, Jon was the first managing director of the JDRF T1D Fund, a growing $75M mission-driven fund focused on venture investments in companies developing solutions for type 1 diabetes. In less than three years, he led the development of the fund’s investment strategy, built an investment team, and led 14 of the fund’s first investments including Semma Therapeutics (acquired by Vertex Pharmaceuticals). Previously, Jon was a market sector leader and executive-in-residence at Partners Healthcare Innovation, leading a team responsible for driving technology translation from research hospitals affiliated with Harvard Medical School. He has held senior venture creation roles, including principal at PureTech Ventures (PRTC) and vice president of new ventures for Enlight Biosciences.

Jon earned a PhD in biological engineering from Massachusetts Institute of Technology as a Howard Hughes Medical Institute fellow and received his BS in bioengineering as Phi-Beta-Kappa co-valedictorian from Rice University.